Log in

ASX:BGTBio-Gene Technology Stock Price, Forecast & News

A$0.19
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.19
Now: A$0.19
A$0.19
50-Day Range
A$0.13
MA: A$0.18
A$0.21
52-Week Range
A$0.08
Now: A$0.19
A$0.32
VolumeN/A
Average VolumeN/A
Market Capitalization$25.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product chemically synthesized nature-identical compound; and Qcide, a natural oil extracted from the leaves of a rare cultivar of an Australian eucalypt, the Gympie Messmate. The company has research collaborations with contract research organizations, including cesar Pty Ltd and Eurofins to assess Flavocide against a range of mites and insect species; and a research collaboration agreement with James Cook University for the development of a tissue culture system in order to support scale up of future Qcide oil production. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9628 4178

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.07 million
Cash FlowA$0.03 per share
Book ValueA$0.03 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$25.24 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BGT News and Ratings via Email

Sign-up to receive the latest news and ratings for BGT and its competitors with MarketBeat's FREE daily newsletter.

Bio-Gene Technology (ASX:BGT) Frequently Asked Questions

How has Bio-Gene Technology's stock been impacted by COVID-19 (Coronavirus)?

Bio-Gene Technology's stock was trading at A$0.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BGT stock has increased by 35.7% and is now trading at A$0.19. View which stocks have been most impacted by Coronavirus.

Has Bio-Gene Technology been receiving favorable news coverage?

News headlines about BGT stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Gene Technology earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBio-Gene Technology.

Who are some of Bio-Gene Technology's key competitors?

Who are Bio-Gene Technology's key executives?

Bio-Gene Technology's management team includes the following people:
  • Mr. Richard Jagger BSC (HONS), M.INTL.BUS, GAICD, MD, CEO & Director
  • Mr. Roger McPherson B.Bus, CPA, GAICD, CFO & Company Sec.
  • Mr. Peter Donald May, Exec. Director of R&D and Director

What is Bio-Gene Technology's stock symbol?

Bio-Gene Technology trades on the ASX under the ticker symbol "BGT."

What is Bio-Gene Technology's stock price today?

One share of BGT stock can currently be purchased for approximately A$0.19.

How big of a company is Bio-Gene Technology?

Bio-Gene Technology has a market capitalization of $25.24 million and generates $1.07 million in revenue each year.

What is Bio-Gene Technology's official website?

The official website for Bio-Gene Technology is www.bio-gene.com.au.

How can I contact Bio-Gene Technology?

The company can be reached via phone at 61 3 9628 4178.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.